Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients with Locally Advanced, Unresectable, Stage III NSCLC
Phase 2
Recruiting
- Conditions
- NSCLCLocally Advanced Lung Carcinoma
- Interventions
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 41
- Registration Number
- NCT06448910
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
Phase 3
Recruiting
- Conditions
- HR+/HER2- Breast CancerAdvanced Breast Cancer
- Interventions
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 184
- Registration Number
- NCT06447623
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2
Not yet recruiting
- Conditions
- Gastric CancerGastro Esophageal Junction Cancer
- Interventions
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 20
- Registration Number
- NCT06447636
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, China
Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Hepatocellular Carcinoma，Bispecific Antibodies, HAIC, Ramucirumab
- Interventions
- Drug: HAIC（Oxaliplatin+ Raltitrexed）、TQB2868、Ramucirumab
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 42
- Registration Number
- NCT06441019
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1100
- Registration Number
- NCT06440902
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
The Antagonistic Effect of Plant Nutrients on Health Damage Caused by Environmental Pollutants
Not Applicable
Not yet recruiting
- Conditions
- InflammationIntestinal Functional Disorder
- Interventions
- Dietary Supplement: placeboDietary Supplement: Compound plant nutrients
- First Posted Date
- 2024-05-31
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 103
- Registration Number
- NCT06437119
A Study of the Intervention of Time-restricted Eating in High-risk Populations of GDM
Not Applicable
Recruiting
- Conditions
- Randomized Controlled StudyDietary HabitsGestational Diabetes MellitusLifestyle Intervention
- Interventions
- Behavioral: Time-limited eating
- First Posted Date
- 2024-05-29
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 240
- Registration Number
- NCT06431997
- Locations
- 🇨🇳
Obstetrics and Gynecology Hospital of Fudan University, Shanghai, Shanghai, China
Exploratory Clinical Study of HRS-4642 Combined With Adebelimab in the Treatment of Advanced Pancreatic Cancer
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 35
- Registration Number
- NCT06427239
- Locations
- 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China
Clinical Study of T3011 Intravesical Instillation for Treatment of NMIBC Patients
Phase 1
Recruiting
- Conditions
- Bladder Cancer
- Interventions
- Biological: Herpes virus T3011 injection
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 20
- Registration Number
- NCT06427291
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer
Phase 2
Not yet recruiting
- Conditions
- Colorectal Cancer
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 129
- Registration Number
- NCT06423937
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath